新型冠状病毒疫苗研发进展及接种意愿分析

doi:10.12183/j.scjpm.2021.0455

摘要/Abstract

摘要： 新型冠状病毒肺炎（COVID-19）自2019年末爆发后迅速造成全球大流行,对公共卫生健康构成众大威胁。引发COVID-19的严重急性呼吸系统综合征冠状病毒-2（SARS-CoV-2）是高致病性病毒,各国采取多种防疫措施均未能从根本控制病毒传播,有效的疫苗对应控制疫情发生发展具有重要作用。各国通力合作,大力研发安全、有效的新型冠状病毒疫苗,本研究综述了新型冠状病毒疫苗研发的进展以及各国民众的疫苗接种意愿。

关键词: 新型冠状病毒肺炎, 新型冠状病毒, 疫苗研发, 接种意愿

中图分类号:

R186

张越, 周小斌, 陈抒怡, 周成林. 新型冠状病毒疫苗研发进展及接种意愿分析[J]. 华南预防医学, 2022, 48(4): 455-459.

参考文献

[1] Zhou P, Yang XL, Wang XG, et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature,2020,579(7798):270-273.
[2] Huang C, Wang Y, Li X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet,2020,395(10223):497-506.
[3] Li Z, Yi Y, Luo X, et al.Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis[J]. J Med Virol,2020,92(9):1518-1524.
[4] Graham BS.Rapid COVID-19 vaccine development[J]. Science,2020,368(6494):945-946.
[5] Lavigne SE.The race for a COVID-19 vaccine[J]. Can J Dent Hyg,2020,54(3):107-109.
[6] Jacobs D.Antibiotics for appendicitis-proceed with caution[J]. N Engl J Med,2020,383(20):1985-1986.
[7] Pulendran B, Ahmed R.Immunological mechanisms of vaccination[J]. Nat Immunol,2011,12(6):509-517.
[8] Wang H, Zhang Y, Huang B, et al.Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2[J]. Cell,2020,182(3):713-721.
[9] Yu JY, Tostanoski LH, Peter L, et al.DNA vaccine protection against SARS-CoV-2 in rhesus macaques[J]. Science,2020,369(6065):806-811.
[10] Jackson LA, Anderson EJ, Rouphael NG, et al.An mRNA vaccine against SARS-CoV-2- preliminary report[J]. N Engl J Med,2020,383(20):1920-1931.
[11] Vartak A, Sucheck SJ.Recent advances in subunit vaccine carriers[J]. Vaccines (Basel),2016,4(2):12-30.
[12] Mueller S, Stauft CB, Kalkeri R, et al.A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates[J]. Vaccine,2020,38(14):2943-2948.
[13] Xia S, Duan K, Zhang Y, et al.Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials[J]. JAMA,2020,324(10):951-960.
[14] Zhang YJ, Zeng G, Pan H, et al.Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial[J]. Lancet Infect Dis,2020,2(21):181-192.
[15] Xia S, Zhang Y, Wang Y, et al.Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial[J]. Lancet Infect Dis,2021,21(1):39-51.
[16] Yang J, Wang W, Chen Z, et al.A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity[J]. Nature,2020,586(7830):572-577.
[17] Smith TRF, Patel A, Ramos S, et al.Immunogenicity of a DNA vaccine candidate for COVID-19[J]. Nat Commun,2020,11(1):2601-2614.
[18] Pagliusi S, Jarrett S, Hayman B, et al.Emerging manufacturers engagements in the COVID-19 vaccine research, development and supply[J]. Vaccine,2020,38(34):5418-5423.
[19] Polack FP, Thomas SJ, Kitchin N, et al.Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine[J]. N Engl J Med,2020,383(27):2603-2615.
[20] Mulligan MJ, Lyke KE, Kitchin N, et al.Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults[J]. Nature,2020,586(7830):589-593.
[21] Reuters. China starts work on plant for mRNA-based COVID-19 vaccine candidate-media[EB/OL].(2020-12-21)[2021-07-24]. https://www.newsbreak.com/news/2129956924593/china-starts-work-on-plant-for-mrna-based-covid-19-vaccine-candidate-media.
[22] Laczko D, Hogan MJ, Toulmin SA, et al.A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice[J]. Immunity,2020,53(4):724-732.
[23] Dai L, Zheng T, Xu K, et al.A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS[J]. Cell,2020,182(3):722-733 e711.
[24] Keech C, Albert G, Cho I, et al.Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine[J]. N Engl J Med,2020,383(24):2320-2332.
[25] Moscato J. Generex biotechnology provides guidance on the safety of Ii-Key peptide vaccines for the development of effective solutions to the SARS-CoV-2 coronavirus pandemic[EB/OL]. (2020-03-19)[2021-07-24]. https://finance.yahoo.com/news/generex-biotechnology-provides-guidance-safety 130010679. html.
[26] Min C. Clover biopharmaceuticals announces positive phase 1 data for its adjuvanted S-trimer COVID-19 vaccine candidates[EB/OL]. (2020-12-04)[2021-07-24]. http://www.cloverbiopharma.com.
[27] Wu S, Zhong G, Zhang J, et al.A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge[J]. Nat Commun,2020,11(1):4081-4087.
[28] Knoll MD, Wonodi C.Oxford-AstraZeneca COVID-19 vaccine efficacy[J]. Lancet,2021,397(10269):72-74.
[29] Balakrishnan VS.The arrival of Sputnik V[J]. Lancet Infect Dis,2020,10(20):1128-1128.
[30] ZEE5 News. COVID-19 vaccine latest ppdate: EpiVacCorona has no negative effect on health of embryo, says Russian watchdog[EB/OL]. (2020-12-30)[2021-07-24]. https://in.news.yahoo.com/covid-19-vaccine-latest-epivaccorona-155025252.html.
[31] Corbett KS, Flynn B, Foulds KE, et al.Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates[J]. N Engl J Med,2020,383(16):1544-1555.
[32] Anderson EJ, Rouphael NG, Widge AT, et al.Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults[J]. N Engl J Med,2020,383(25):2427-2438.
[33] Reuters. Turkey says China’s Sinovac COVID vaccine 91.25% effective in late trials[EB/OL]. (2020-12-24)[2021-07-24]. http://www.asahi.com/sp/ajw/articles/14059486.
[34] Zhu FC, Li YH, Guan XH, et al.Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial[J]. Lancet,2020,395(10240):1845-1854.
[35] Yang SL, Li Y, Dai LP, et al.Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials[J]. Lancet Infect Dis,2021, 21(8):1107-1119.
[36] Kaabi NA, Zhang YT, Xia SL, et al.Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults[J]. JAMA, 2021,326(1):35-45.
[37] Lazarus JV, Ratzan SC, Palayew A, et al.A global survey of potential acceptance of a COVID-19 vaccine[J]. Nat Med,2020,1(26):1-4.
[38] Wang J, Jing R, Lai X, et al.Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China[J]. Vaccines (Basel),2020,8(3):482-496.
[39] Harapan H, Wagner AL, Yufika A, et al.Acceptance of a COVID-19 vaccine in Southeast Asia: A cross-sectional study in Indonesia[J]. Front Public Health,2020,8:381-388.
[40] Mohaithef M, Padhi BK.Determinants of COVID-19 vaccine acceptance in Saudi Arabia: A web-based national survey[J]. J Multidiscip Health,2020,13:1657-1663.
[41] Garcia LY, Cerda AA.Contingent assessment of the COVID-19 vaccine[J]. Vaccine,2020,38(34):5424-5429.
[42] Reiter PL, Pennell ML, Katz ML.Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated?[J].Vaccine,2020,38(42):6500-6507.
[43] Malik AA, McFadden SM, Elharake J, et al. Determinants of COVID-19 vaccine acceptance in the US[J]. E Clinical Medicine,2020,26:100495-100503.
[44] Sarasty O, Carpio CE, Hudson D, et al.The demand for a COVID-19 vaccine in Ecuador[J]. Vaccine,2020,38(51):8090-8098.
[45] Salali GD, Uysal MS.COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey[J]. Psychol Med,2020,50(1):1-3.